6-溴-3-吡嗪胺 | 88497-27-2

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡嗪类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 6-溴-3-吡嗪胺
• 中文别名: 3-氨基-6-溴哒嗪；3-氨基-6-溴吡嗪
• 英文名称: 6-bromopyridazin-3-amine
• 英文别名: 3-amino-6-bromopyridazine；6-bromopyridazin-3-ylamine；3-Amino-6-brompyridazin
• CAS: 88497-27-2
• 化学式: C₄H₄BrN₃
• 分子量: 174.0
• InChiKey: FXTDHDQFLZNYKW-UHFFFAOYSA-N

物化性质

• 熔点：
  194 °C
• 沸点：
  353.2±22.0 °C(Predicted)
• 密度：
  1.844±0.06 g/cm3(Predicted)
• pKa：
  4.06±0.10 (Predicted,Most Basic Temp: 25 °C)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  51.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S22,S26,S36/37/39
• 危险类别码：
  R20/21/22,R36/37/38
• 海关编码：
  29335990
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  应存放在室温、干燥且密封的环境中。

SDS

Name:	6-Bromo-3-pyridazinamine Material Safety Data Sheet
Synonym:	6-Bromo-3-pyridazinylamine
CAS:	88497-27-2

Section 1 - Chemical Product MSDS Name:6-Bromo-3-pyridazinamine Material Safety Data Sheet
Synonym:6-Bromo-3-pyridazinylamine

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
88497-27-2	6-Bromo-3-pyridazinamine	97+	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 88497-27-2: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: beige
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 203-207 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C4H4BrN3
Molecular Weight: 174

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Dust generation.
Incompatibilities with Other Materials:
Oxidizing agents, acids, acid chlorides.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, carbon dioxide, hydrogen bromide, bromine.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 88497-27-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
6-Bromo-3-pyridazinamine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing group:

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 22 Do not breathe dust.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 88497-27-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 88497-27-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 88497-27-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-溴-3-吡嗪胺 在 sodium hydroxide 、 palladium on activated charcoal 作用下， 生成 哒嗪-3-胺
  参考文献：
  名称：

  Pyridazine Derivatives. II.¹ An Improved Synthesis of 3-Aminopyridazine

  摘要：

  DOI：

  10.1021/ja01641a043
• 作为产物：
  描述：

  3,6-二溴哒嗪 在 氨 作用下， 生成 6-溴-3-吡嗪胺
  参考文献：
  名称：

  杂环研究中的化学研究。4. Mitteilung。哒嗪类衍生物

  摘要：

  描述了许多3-和6-位取代的哒嗪和4-甲基哒嗪用于药理研究。某些3,6-二烷氧基-哒嗪具有良好的抗惊厥性质。3,6-二肼基哒嗪在其药理特性上类似于降血压药“ A presoline”和“ Nepresol”。3-氨基-6-氯哒嗪的磺基衍生物具有优异的抗菌作用。

  DOI：

  10.1002/hlca.19540370115

文献信息

• [EN] INHIBITORS OF THE WNT SIGNALLING PATHWAYS<br/>[FR] INHIBITEURS DES VOIES DE SIGNALISATION WNT
  申请人：BAYER PHARMA AG

  公开号：WO2015140196A1

  公开（公告）日：2015-09-24

  The present invention relates to inhibitors of the Wnt signalling pathways of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper- proliferative disorder, as a sole agent or in combination with other active ingredients.

  本发明涉及通式（I）所述和定义的Wnt信号通路抑制剂，涉及制备该类化合物的方法，有用于制备该类化合物的中间化合物，包含该类化合物的药物组合物和组合物，以及利用该类化合物制造用于治疗或预防疾病的药物组合物，特别是用作唯一药剂或与其他活性成分组合使用时，用于治疗或预防过度增殖性疾病。
• Rational design, synthesis and testing of novel tricyclic topoisomerase inhibitors for the treatment of bacterial infections part 1
  作者：R. Kirk、A. Ratcliffe、G. Noonan、M. Uosis-Martin、D. Lyth、O. Bardell-Cox、J. Massam、P. Schofield、S. Hindley、D. R. Jones、J. Maclean、A. Smith、V. Savage、S. Mohmed、C. Charrier、A-M. Salisbury、E. Moyo、R. Metzger、N. Chalam-Judge、J. Cheung、N. R. Stokes、S. Best、M. Craighead、R. Armer、A. Huxley

  DOI：10.1039/d0md00174k

  日期：——

  and topoisomerase IV inhibitors that demonstrate potent activity against a range of Gram-positive and selected Gram-negative organisms, including clinically-relevant and drug-resistant strains. In part 1, we present a detailed structure activity relationship (SAR) analysis that led to the discovery of our previously disclosed compound, REDX05931, which has a minimum inhibitory concentration (MIC) of

  针对细菌感染的药物有效性令人震惊的下降，迫切需要开发新的抗菌剂来绕过细菌耐药机制。我们在此报告了一系列 DNA 促旋酶和拓扑异构酶 IV 抑制剂，它们对一系列革兰氏阳性和选定的革兰氏阴性生物体（包括临床相关和耐药菌株）表现出有效的活性。在第 1 部分中，我们提出了详细的构效关系 (SAR) 分析，导致我们发现了我们之前公开的化合物 REDX05931，该化合物对耐氟喹诺酮类金黄色葡萄球菌的最小抑制浓度 (MIC) 为 0.06 μg mL -1。虽然在体外 hERG 和 CYP 抑制阻止了进一步的发展，它验证了一种合理的设计方法来解决这一紧迫的未满足的医疗需求，并为进一步优化提供了一个支架，在第 2 部分中介绍。
• Discovery of CPI-1612: A Potent, Selective, and Orally Bioavailable EP300/CBP Histone Acetyltransferase Inhibitor
  作者：Jonathan E. Wilson、Gaurav Patel、Chirag Patel、Francois Brucelle、Annissa Huhn、Anna S. Gardberg、Florence Poy、Nico Cantone、Archana Bommi-Reddy、Robert J. Sims、Richard T. Cummings、Julian R. Levell

  DOI：10.1021/acsmedchemlett.0c00155

  日期：2020.6.11

  inflammatory disorders, and neurodegeneration. A novel, highly potent, orally bioavailable EP300/CBP histone acetyltransferase (HAT) inhibitor, CPI-1612 or 17, was developed from the lead compound 3. Replacement of the indole scaffold of 3 with the aminopyridine scaffold of 17 led to improvements in potency, solubility, and bioavailability. These characteristics resulted in a 20-fold lower efficacious

  组蛋白乙酰基转移酶，CREB结合蛋白（CBP）和EP300是主要的转录共调节剂，与多种疾病有关，例如癌症，炎症性疾病和神经变性。从铅化合物3开发了一种新型的高效口服生物利用EP300 / CBP组蛋白乙酰转移酶（HAT）抑制剂CPI-1612或17。用17的氨基吡啶支架替换3的吲哚支架导致效力，溶解度和生物利用度的提高。在JEKO-1肿瘤小鼠异种移植研究中，这些特性导致17的有效剂量相对于铅3降低了20倍。
• [EN] TRICYCLIC MODULATORS OF TNF SIGNALING<br/>[FR] MODULATEURS TRICYCLIQUES DE LA SIGNALISATION DU TNF
  申请人：ABBVIE INC

  公开号：WO2016168641A1

  公开（公告）日：2016-10-20

  The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, prodrugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.

  这项发明提供了三环杂环化合物，其药用盐、前药、生物活性代谢物、立体异构体和同分异构体，其中变量在此处定义。该发明的化合物可能对治疗免疫和肿瘤疾病有用。
• [EN] DIAZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE<br/>[FR] DÉRIVÉS DE DIAZAINDOLE ET LEUR UTILISATION DANS L'INHIBITION DE KINASE C-JUN N-TERMINALE
  申请人：EISAI R&D MAN CO LTD

  公开号：WO2010015803A1

  公开（公告）日：2010-02-11

  The invention relates to diazaindole derivatives represented by the general formula (I): where A, E, G, R1, R2, R3 and R4 are defined herein, or pharmaceutically acceptable salts thereof, their use in the inhibition of c-Jun N-terminal kinase (JNK) activity, their use in medicine and particularly in the treatment of neurodegenerative disorders, inflammatory diseases, autoimmune diseases and/or organ failure. The invention also provides processes for the manufacture of said diazaindole derivatives and compositions containing them.

  本发明涉及由通用公式（I）表示的哒嗪吲哚衍生物：其中A、E、G、R1、R2、R3和R4在本说明书中定义，或其药用可接受的盐，它们用于抑制c-Jun N末端激酶（JNK）活性，它们用于医药领域，特别是在治疗神经退行性疾病、炎症性疾病、自身免疫性疾病和/或器官衰竭方面的应用。本发明还提供了制造所述哒嗪吲哚衍生物的方法以及包含它们的组合物。